Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Neoplasms

Symptoms and General Pathology

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Nutritional and Metabolic Diseases

Rare Diseases

Kidney Diseases

Adenoma

Kidney Failure, Chronic

Hyperplasia

Hyperaldosteronism

Adrenal Hyperplasia, Congenital

Adrenogenital Syndrome

Hypokalemia

Potassium Deficiency

Syndrome

Renal Insufficiency, Chronic

Renal Insufficiency

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Endocrine System Diseases

Disorders of Sex Development

Congenital Abnormalities

Urogenital Abnormalities

Genetic Diseases, Inborn

Metabolism, Inborn Errors

Steroid Metabolism, Inborn Errors

Metabolic Diseases

Gonadal Disorders

Chronic Disease

Disease Attributes

Water-Electrolyte Imbalance

Chronic Graft Versus Host Disease

Congenital Adrenal Hyperplasia

21-hydroxylase Deficiency

Hyperadrenalism

All Drugs and Chemicals

Channel Blockers

Diuretics

Sodium Channel Blockers

Diuretics, Potassium Sparing

Mineralocorticoid Receptor Antagonists

Mineralocorticoids

Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism

Unilateral adrenalectomy in patients with unilateral disease

Troy Puar, MRCP

Troy Puar

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands).

It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.

The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.

Outcome of Patients With Primary Aldosteronism

Long-term Outcomes in Patients With Primary Aldosteronism After Treatment

incidence of new cardiovascular events including acute myocardial infarction, revascularisation percutaneously, coronary artery bypass graft, stroke, admission for congestive cardiac failure, atrial fibrillation

incidence of worsening chronic kidney disease, decline of glomerular filtration rate by 15ml/min from at least 60m/min

rate of decline of glomerular filtration rate

Identify variables that are more common in patients with unilateral disease

Identify variables that are more common in patients with positive blood pressure response

Singapore General Hospital

Changi General Hospital

Neoplasms, Second Primary

Antineoplastic Agents

Anti-Infective Agents

Trastuzumab

Bleomycin

Cisplatin

Antineoplastic Agents, Immunological

Anti-Bacterial Agents

Antibiotics, Antitubercular

Patients with toxicity during/after treatment with anthracylines.

Patients without toxicity during/after treatment with anthracylines.

Patients with toxicity during/after treatment with trastuzumab.

Patients without toxicity during/after treatment with trastuzumab.

Patients with toxicity during/after treatment with cisplatin.

Patients without toxicity during/after treatment with cisplatin.

Patients with toxicity during/after treatment with bleomycin.

Patients without toxicity during/after treatment with bleomycin.

Chemotherapy regimen containing anthracyclines.

Anthracyclines

Systemic treatment including trastuzumab.

J.A. Gietema, MD, PhD

L.C. Steggink, MD

Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.

Urine sample, blood sample, germline DNA, skin fibroblasts.

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem Cells

Comparison between iPSC-derived cells from toxicity cases and controls, for each of the four different agents.

Correlate the findings from the iPSC-derived cells with the clinical phenotype of (cardiovascular) toxicity, assessed by circulating biomarkers and cardiac or vascular imaging.

University Medical Center Groningen

Skin and Connective Tissue Diseases

Breast Neoplasms

Central Nervous System Depressants

Herbal and Botanical

Other Dietary Supplements

Benzocaine

Tannic Acid

Group 1 (Experimental intervention): Participants assigned to this group will receive standard chemotherapy treatment plus a dietary program, and sedentary time reduction strategies, program and a Fitbit monitor. If you are randomized into this group, you will be asked to follow TRE, will receive nutritional education and individualized recommendations on improving diet quality and healthy eating practices, and given to strategies to work towards reducing sedentary time. These components will be gradually introduced over the 24-week program.

Group 2 (Non-experimental intervention): Participants randomized to this group will receive standard chemotherapy treatment plus a single, group-based "nutrition during cancer" class, as well as a copy of Canada's Food Guide, physical activity guidelines, and a Fitbit monitor. You will be asked to only make dietary changes if they are recommended within the class or by your doctor, and to maintain your usual timing and number of meals consumed per day. Throughout the 24-week period, you will receive seven brief phone calls from a study staff member to ask about your symptoms and provide support. After the end of the study, participants in this group will be offered a one-one-one counselling session with a registered dietitian.

1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or "fast" by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.
2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.
3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life.

Time restricted eating, nutrition education, and sedentary time reduction strategies

Rachel Sherrington, Bkin

Richard Thrompson, PhD

Richard Thompson, PhD

Background \& Rationale:

Breast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases). In Canada, early stage BC mortality rates have decreased by 48% over the past 30 years as a result of advances in prevention, detection, and treatment. However, competing risks for mortality from non-cancer causes have emerged, where cardiovascular disease (CVD) is now a leading cause of death for BC survivors. The direct toxic effects of BC treatment on the heart (cardiotoxicity) are well characterized by the investigators and many others, as a contributor to elevated cardiovascular risk. However, BC treatment and the associated lifestyle changes (i.e. physical inactivity, poor diet quality, stress) are increasingly recognized to also strongly affect metabolism negatively manifesting as insulin resistance, dyslipidemia and adipose tissue (fat) accumulation. These adverse metabolic changes are strongly linked to CVD risk and represent a currently underappreciated contributor to the elevated CVD risk among BC survivors. Preliminary data and recent publications demonstrate that regional fat accumulation occurs during BC treatment and that the fat burden in key locations is associated with poor cardiorespiratory health. A trigger of these adverse metabolic and inflammatory effects is excess fat specifically within ectopic fat (viscera, intermuscular, or hepatic) regions. In 2019, a member of the study team found that the volume of visceral and intermuscular but not subcutaneous fat at BC diagnosis were linearly associated with CVD events within 6 years, even among those with normal BMI and after adjustment for pre-existing CVD risk factors and for BC treatment type. Using MRI, investigators found that \~1 year after chemotherapy, BC survivors had significantly larger depots of visceral fat (49% larger) and thigh intermuscular fat (41% larger) compared to age and sex-matched controls, despite similar BMI and subcutaneous fat volumes in the two groups. Investigators also showed that the fat fraction within the thigh muscle and visceral fat volumes independently explained \~50% of the variation in cardiorespiratory fitness (measured by peak VO2). In particular, peak VO2 is one of the most powerful predictors of all-cause and CVD mortality and health care costs, and is the most consistently reported negative sequelae after treatment for BC. Unfortunately, there are no known therapies to recover long-term myocardial damage (i.e. cell death, fibrosis) from cancer therapies. There are several reasons to target fat as a therapeutic target in BC patients: 1) The study team have compelling preliminary data showing accelerated formation of ectopic fat during BC treatment. 2) Investigator's recent data showed that high fat content in key fat pools was associated with reduced peak VO2. 3) The burden of fat and the associated metabolic abnormalities are dynamic and malleable, and thus highly treatable.

Research Question \& Objectives:

The primary purpose of this study is to evaluate the effect of a behavioural intervention involving supported time-restricted eating (TRE), diet quality improvements, and reduced sedentary time versus usual cancer and nutrition care in BC patients receiving chemotherapy treatment on ectopic fat, cardiometabolic profile, and chemotherapy outcomes. The investigators hypothesize that the intervention will attenuate the growth of ectopic fat during chemotherapy and reduce chemotherapy symptoms.

Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women

Information collected during the study will be used in analyses and will be published/ presented to the scientific community at meetings and in journals. In addition, study data without any identifying information will be shared with the research team at the University of Toronto, where the study is also taking place.

Using blood work to determine insulin resistance, this includes HOMA-IR (mg/dL), hemoglobin A1c (mg/dL), lipid profile (mg/dL), and fasting glucose (mg/dL).

Measurement of abdominal circumference at the level of the umbilicus, recorded to the nearest 0.5 cm, and measurement of circumference of the hips to the nearest 0.5 cm to calculate waist-to-hip ratio.

Manually measured using a stethoscope and sphygmomanometer in a seated position after five minutes of quiet rest. The average of 2 measurements, taken 60 seconds apart that are within 6 mmHg will be taken.

Measure of leptin and adiponectin (hormones involved in fat regulation) in blood recorded in ng/mL and ug/mL respectively.

Descriptive data and chemotherapy outcomes, as well as tracking long-term health effects of participation through participants' electronic medical records.

Measure of cytokines IL-6 and TNF-a in blood recorded in pg/mL.

Volume of time spent physically active measured by Fitbit Inspire 2 wrist band.

Dietary intake will be assessed by 3-day food diary that is to be recorded over 2 consecutive weekdays and 1 weekend day, and will be collected using the Canadian version of the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24-Canada).

Status as self-reported by participants in a qualitative demographics questionnaire. Participants may respond yes or no. Participants who smoke may indicate a worse outcome.

Thigh intermuscular and intramuscular fat volumes as measured by MRI.

Volume of fat in the hepatocytes in the liver as measured by MRI.

Subcutaneous fat volumes that surround the abdomen as measured by MRI.

Defined by the National Cholesterol Education Program Adult Treatment Panel, metabolic syndrome is determined by the presence of 3 or more of the following: abdominal obesity defined by waist circumference (men \>102cm, women \>88cm), triglycerides ≥150mg/dL, fasting glucose ≥110mg/dL, HDL cholesterol \<40mg/dL for men and \<50mg/dL for women, and blood pressure of ≥130/≥85mmHg. Z-scores of 0 are equal to the mean. Anything above 0 for each risk listed above (excluding HDL cholesterol) indicates higher risk of CVD. Since HDL cholesterol is healthy, higher z-scores indicate lower risk of CVD. Z-scores rarely fall outside a range of -3 to 3.

Using the Framingham risk score to determine cardiovascular disease risk calculated using the Canadian Cardiovascular Society scoring system for age, sex, total cholesterol (mg/dL), high-density lipoprotein (mg/dL), treated or untreated systolic blood pressure (mmHg), diabetes, and smoking status (self-reported in questionnaires). Each category listed above is also assigned a numeric value. To find risk, one must total their points together from each category. The minimum value ranges from -3 or less points to a maximum value range of 21+ points. -3 or less points indicates a very low risk of cardiovascular disease, and 21+ points indicates a high risk of cardiovascular disease.

Maximal amount of oxygen consumed during a cardiopulmonary exercise test on a cycle ergometer measured by mL/kg/min to indicate cardiorespiratory fitness.

Canadian Institutes of Health Research (CIHR)

University of Alberta

Testicular Neoplasms

Endocrine Gland Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Testicular Diseases

Elisabeth G.E. de Vries, MD, PhD

BACKGROUND:

Evidence has emerged that patients cured with cisplatin-bleomycin chemotherapy from disseminated testicular cancer (TC) develop a large number of cardiovascular risk factors (CRF) several years later. Recently, we observed an increased incidence of cardiac events 10-20 years after chemotherapy, possibly as a result of increased occurrence of CRF. Additional cardiovascular damage was observed after treatment: disturbed diastolic function of the left ventricle, microalbuminuria and increased endothelial damage parameters. Furthermore, a metabolic syndrome (syndrome X) with insulin-resistance, dyslipidemia, hypertension and endothelial damage was found in about one third of our cured patients. The investigators hypothesize that endothelial damage and metabolic changes caused by the bleomycin and cisplatin chemotherapy are the main causes for the observed increase in cardiovascular disease in these young cancer survivors. Genetic susceptibility may be an important determinant of individual risk of toxicity in individual patients.

PURPOSE:

1. To identify risk factors for cardiovascular disease (CVD) following testicular cancer.
2. To obtain insight into the pathway(s) of CVD development, by examining whether clinical CVD following testicular cancer is associated with a preceding unfavorable cardiovascular risk factor profile and/or with treatment-related factors.
3. To investigate genetic polymorphisms in pathogenetically important pathways that are potentially involved in the development of treatment related cardiovascular morbidity following testicular cancer.

PATIENTS AND METHODS:

Patients with non-seminomatous testicular cancer who have been uniformly treated with orchidectomy and cisplatin-bleomycin combination chemotherapy at the University Hospital Groningen, The Netherlands, since 1977 but before 2000 are eligible. 380 patients with non-seminomatous testicular cancer fulfill these criteria. A close routine follow-up of these patients after treatment has been done at the University Hospital Groningen. Clinical characteristics of these patients, treatment details including outcome and long-term follow-up are being registered systematically. From all patients who agree to participate assessment of their cardiovascular risk factors and the presence of subclinical cardiovascular damage will be performed by means of several measurement techniques. Also genomic DNA will be collected for studies on polymorphisms in pathogenetically important pathways. For the total cohort of patients several different late effects phenotypes of cardiovascular damage and cardiovascular risk factor patterns will be derived from the available data. These toxicity phenotypes will be used to select cases and controls from the total cohort to test candidate genetic polymorphisms on their association with occurrence of toxicity. The association of the different genetic polymorphisms with the toxicity phenotype will be estimated by comparing cases with different toxicity phenotypes with controls without that phenotype.

POSSIBLE RESULTS This research will provide insight into the pathogenesis of cardiovascular disease after treatment for testicular cancer. The main outcome will be the possibility to select individually those patients who are likely to have an increased risk to encounter specific cardiovascular toxicity during or after chemotherapy treatment for TC. This will provide opportunities for the tailoring of potential toxic treatment and/or guide primary and secondary prevention strategies for serious side effects of chemotherapy treatment.

For cured patients with complete data on cardiovascular risk factors and presence of subclinical cardiovascular damage only DNA will be collected.

Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity

Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157)

Dutch Cancer Society

Heart and Blood Diseases

Pheochromocytoma

Paraganglioma

Cardiomyopathies

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Paragangliomas 1

Neuroendocrine Tumor

Neuroepithelioma

Vasoconstrictor Agents

Respiratory System Agents

Antihypertensive Agents

Epinephrine

Racepinephrine

Epinephryl borate

Patients included in this cohort (n=50) are those who are diagnosed of Pheochromocytoma / Paraganglioma, willing to consent for the study and not on α-blockade at the time of recruitment into study, while can be on any other anti hypertensives

Patients in this group, besides the usual evaluation of Pheochromocytoma / Paraganglioma, will also undergo detailed cardiac and vascular evaluation, which will be done at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision The cardiovascular evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses

This is a contemporary age- and gender-matched control group This group includes 10 newly detected (within 3 months) Essential Hypertensive patients, who will undergo treatment with standard anti- HT medications Cardiac evaluation will be done at baseline and after 3 months of anti hypertensive medications

This is a contemporary age- and gender-matched control group This group includes 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer Cardiac evaluation will be done at the start of study and after 6 months

Observational study

Gaurav Agarwal, MS,DNB,PDC

PHEOCHROMOCYTOMA (PCC)/ PARAGANGLIOMA are catecholamine secreting tumors with varied manifestations. Besides hypertension, PCC patients may have subclinical to overt cardiac and vascular dysfunction, which are important to recognize to minimize perioperative morbidity and mortality. Cardiovascular (CV) dysfunction can be in the form of hypertension, left ventricular (LV) hypertrophy, heart failure, cardiomyopathy, dysrhythmias, angina and Myocardial infarction. Literature search revealed a few retrospective and a few prospective studies, including one prospective follow up study conducted at SGPGIMS to document CV changes in PCC. Our institutional study was the first to document the nature and extent of CV dysfunction and cardiomyopathy and their reversal after surgical cure. The studies revealed that PCC patients had significantly higher LV mass index, higher LV diastolic dysfunction, subclinical impaired LV systolic function. Earlier studies postulated apparent improvement in various cardiac indices even with selective α-blockade and continued after surgical cure, with near normalization at 3 -6 months postoperatively. Detailed cardiac and vascular evaluation in PCC patients can be of help in preoperative optimization of cardiac risk and may provide prognostic information The literature on PCC-mediated CV dysfunction and catecholamine cardiomyopathy is largely limited to case reports and retrospective studies, with few reports of their reversal after curative PCC operations. Whether the duration of disease influence the function of heart was not apparently addressed in earlier trials. Trials that established the differences in the degree of cardiac dysfunction between normotensive and hypertensive PCC patients involved smaller proportion of study subjects. Sub clinical changes in endomyocardium was presumed but not objectively assessed and hence its reversal after surgical cure is uncertain.

The aim of this research is to study the cardiac and vascular changes in Pheochromocytoma/ Paraganglioma patients and their reversal following curative surgery

The aim of this research is to study the cardiac and vascular changes in Pheochromocytoma/ Paraganglioma patients and their reversal following curative surgery

This prospective, case-control study is conducted at SGPGIMS, Lucknow, India, tertiary care referral institute, between January 2019 and September 2021 after approval from institutional ethics committee. The study group includes 50 biochemically and histopathology proven PCC /Paraganglioma patients, who after 1 to 3 weeks of α-adrenoceptor blockade with oral prazosin undergo primary laparoscopic or open surgery. Cure of hypercatecholaminism will be documented by normal 24-hour urinary fractionated metanephrine values at 7-10 days postoperatively.

Two contemporary age- and gender-matched control groups includes 10 newly detected (withtin 3 months) Essential Hypertensive (E-HT) patients, who will undergo treatment with standard anti- HT medications and 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer.

METHODOLOGY

Patients in the study group, besides the usual evaluation of PCC, also undergo detailed cardiac and vascular evaluation, at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision and in control groups - E-HT controls, cardiac evaluation is done at diagnosis and after 3 months of anti HT medications ; in Healthy individuals, cardiac evaluation is done at the start of study and after 6 months.

The CV evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses

Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma

Prospective Cohort Study of Objective Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma and Their Reversal Following Curative Surgery

Left ventricle end systolic and end diastolic diameter in millimeter

Left ventricle end systolic and end diastolic volume dimensions in milliliter

Left ventricle Ejection fraction by Simpsons method in percentage

Peak velocities of the early (E) and Late phase (A) of the mitral valve inflow pattern and their ratio in centimeter per second

Flow rate across mitral valve in centimeter per second and deceleration time in millisecond

Left ventricle global longitudinal strain in percentage

Left ventricle global circumferential strain in percentage

Flow mediated dilation of brachial artery diameter pre and post sublingual isosorbide dinitrate in millimeter

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Professor of Endocrine Surgery

Musculoskeletal Diseases

Prostatic Neoplasms

Diabetes Mellitus

Obesity

Metabolic Syndrome

Hyperlipidemias

Hyperlipoproteinemias

Bone Diseases

Prostatic Diseases

Insulin Resistance

Hyperinsulinism

Glucose Metabolism Disorders

Dyslipidemias

Lipid Metabolism Disorders

Vitamins

Androgens

Acetic Acid

Retinol acetate

Webbers Natural apple cider vinegar pills (NPN: 80021269), enteric coated. Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months.

Placebo pills will be provided by our hospital pharmacy, and patients will be given the same instructions as in the treatment arm.

Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months

https://www.webbernaturals.com/en-ca/apple-cider-vinegar-500-mg-capsules/

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Outcome of Patients With Primary Aldosteronism	NCT04428827	Primary Aldoste... Primary Aldoste... Primary Aldoste... Adrenalectomy; ... Mineralocortico... Mineralocortico... Cardiovascular ... Chronic Renal D... Hypokalemia	Unilateral adre...	14 Years - 100 Years	Changi General Hospital
Investigating Cardiovascular Adverse Events Related to Cancer Treatment	NCT03199300	Toxicity Due to... Cardiovascular ... Cancer, Treatme...	Anthracyclines Trastuzumab Cisplatin Bleomycin	18 Years -	University Medical Center Groningen
Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women	NCT05432856	Cardiovascular ... Cardiovascular ... Metabolic Disea...	Time restricted...	18 Years -	University of Alberta
Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity	NCT00161174	Non-seminomatou...		-	University Medical Center Groningen
Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma	NCT05082311	Pheochromocytom... Paraganglioma Cardiovascular ...	Observational s...	7 Years -	Sanjay Gandhi Postgraduate Institute of Medical Sciences
Akkermansia Muciniphilia and Metabolic Side Effects of ADT	NCT05802121	Prostate Cancer Metabolic Syndr... Obesity Cardiovascular ... Bone Diseases Hyperlipidemias Diabetes	Apple Cider Vin... Placebo	18 Years -	Western University

Spots Global Cancer Trial Database for cardiovascular morbidity